Skip to content
Disclosery

Aisling Capital Management LP

Follow

13F filer, CIK 1766721, NEW YORK, NY

Aisling Capital Management LP reported $476,288,954 across 13 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-05. Its ten largest share positions make up 99.49% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001766721-26-000002

Period
2026-03-31
Reported value
$476M
Holdings
13
Top 10 weight
99.49%
New
1
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
BBOTadded+453,393$4.06M
EPRXnew+325,000$2.35M
GLUEadded+83,333$1.37M
CMPSadded+233,918$1.29M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CALCexited-521,114-$3.43M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001766721-26-000002, largest first. % of portfolio is the value over $476,288,954, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BBIOBRIDGEBIO PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 6,068,125 shares; 2024Q4: 6,068,125 shares; 2025Q1: 6,068,125 shares; 2025Q2: 6,068,125 shares; 2025Q3: 6,089,611 shares; 2025Q4: 5,089,611 shares; 2026Q1: 5,089,611 shares 5,089,611$378M79.35%0Timeline
SNDXSYNDAX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,025,000 shares; 2024Q4: 1,025,000 shares; 2025Q1: 1,025,000 shares; 2025Q2: 1,316,806 shares; 2025Q3: 1,316,806 shares; 2025Q4: 1,316,806 shares; 2026Q1: 1,316,806 shares 1,316,806$30.8M6.46%0Timeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,472,331 shares; 2024Q4: 1,472,331 shares; 2025Q1: 1,472,331 shares; 2025Q2: 1,472,331 shares; 2025Q3: 1,472,331 shares; 2025Q4: 1,472,331 shares; 2026Q1: 1,555,664 shares 1,555,664$25.6M5.37%+83,333Timeline
BCAXBICARA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 568,919 shares; 2024Q4: 568,919 shares; 2025Q1: 568,919 shares; 2025Q2: 568,919 shares; 2025Q3: 568,919 shares; 2025Q4: 568,919 shares; 2026Q1: 568,919 shares 568,919$11.3M2.38%0Timeline
BBOTBRIDGEBIO ONCOLOGY THERAPEUTQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 564,625 shares; 2025Q4: 564,625 shares; 2026Q1: 1,018,018 shares 1,018,018$9.11M1.91%+453,393Timeline
CMPSCOMPASS PATHWAYS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 964,500 shares; 2024Q4: 964,500 shares; 2025Q1: 1,198,418 shares; 2025Q2: 1,198,418 shares; 2025Q3: 1,198,418 shares; 2025Q4: 1,198,418 shares; 2026Q1: 1,432,336 shares 1,432,336$7.92M1.66%+233,918Timeline
SRRKSCHOLAR ROCK HLDG CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 77,031 shares; 2025Q4: 77,031 shares; 2026Q1: 77,031 shares 77,031$3.79M0.8%0Timeline
BMEABIOMEA FUSION INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 798,757 shares; 2024Q4: 798,757 shares; 2025Q1: 798,757 shares; 2025Q2: 2,048,757 shares; 2025Q3: 2,048,757 shares; 2025Q4: 2,048,757 shares; 2026Q1: 2,048,757 shares 2,048,757$3.13M0.66%0Timeline
EPRXEUPRAXIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 325,000 shares 325,000$2.35M0.49%newTimeline
URGNUROGEN PHARMA LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 108,000 shares; 2026Q1: 108,000 shares 108,000$1.94M0.41%0Timeline
ACRSACLARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 434,455 shares; 2024Q4: 434,455 shares; 2025Q1: 434,455 shares; 2025Q2: 434,455 shares; 2025Q3: 434,455 shares; 2025Q4: 434,455 shares; 2026Q1: 434,455 shares 434,455$1.63M0.34%0Timeline
MRKRMARKER THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 314,286 shares; 2024Q4: 325,370 shares; 2025Q1: 325,370 shares; 2025Q2: 325,370 shares; 2025Q3: 325,370 shares; 2025Q4: 325,370 shares; 2026Q1: 325,370 shares 325,370$423K0.09%0Timeline
OKURONKURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 88,607 shares; 2025Q1: 88,607 shares; 2025Q2: 88,607 shares; 2025Q3: 88,607 shares; 2025Q4: 88,607 shares; 2026Q1: 88,607 shares 88,607$367K0.08%0Timeline

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CALCCALCIMEDICA INC521,114$3.43Mshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001766721-26-000002 base2026-05-05acceptance time not in the bulk data set